Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom

Elberink, Joanne N.G. Oude; Monchy, J. G. R. De; Heide, S. van der; Guyatt, Gordon; Dubois, Anthony

doi:10.1067/mai.2002.125827

Cited by 151 publications

(153 citation statements)

References 14 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…The relationship between the different publications (Oude Elberink et al [82][83][84]87 ) is not clear and it is possible that one publication reports data on people who are also included in another publication. Therefore, for the purpose of this review it is assumed that the publications of Oude Elberink relate to two separate RCTs, one RCT of VIT for the treatment of adults with a history of anaphylactic reaction to yellow jacket sting (Oude Elberink et al [82][83][84] ) and one RCT of VIT for the treatment of adults with a history of cutaneous reaction to yellow jacket sting (Oude Elberink et al 87 ). References of included studies…”

Section: Health-related Quality Of Lifementioning

confidence: 99%

“…However, these individuals may experience anxiety related to the possibility of a future sting, which may impact on their QoL. QoL has been assessed in a series of papers by Oude Elberink, [82][83][84]87 and a tool has been developed to specifically measure this: the Vespid Allergy Quality of Life Questionnaire (VQLQ). 84 The VQLQ has been found to have adequate cross-sectional and longitudinal validity.…”

Section: Health-related Quality Of Lifementioning

confidence: 99%

See 1 more Smart Citation

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

Hockenhull

Elremeli²,

Cherry³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are ...

show abstract

Section: Health-related Quality Of Lifementioning

confidence: 99%

Section: Health-related Quality Of Lifementioning

confidence: 99%

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

Hockenhull

Elremeli²,

Cherry³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…49 VIT improves QoL in vespid venom-allergic patients even when they do not experience a resting. 50 In a study where patients were offered a sting challenge after VIT, 80% of patients reported a significantly increased QoL after tolerating a sting challenge. 51 In contrast, therapy with the AAI alone was shown to negatively impact on health-related QoL, 50,52 a significantly increased burden for patients 53 and a higher level of anxiety and depression.…”

Section: Quality Of Lifementioning

confidence: 99%

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

Sturm

Varga

Roberts

et al. 2017

Allergy

385

528

View full text Add to dashboard Cite

Hymenoptera venom allergy is a potentially life‐threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic‐allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life‐threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1‐antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence‐based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta‐analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom‐allergic children and adults to prevent further moderate‐to‐severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence‐based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.

show abstract

“…44 VIT also significantly improves the quality of life in venom--treated individuals. 45,46 VIT is the treatment of choice in patients fulfilling both clinical and immunological criteria: a severe generalized reaction to sting in the past medical history with respiratory or circulatory symptoms or both (grade III-IV according to Mueller) and the presence of vsIgE-antibodies to the venom of the responsible Hymenoptera species (any positive result of skin prick tests or intradermal tests or vsIgE, or How to treat allergic reactions to field stings? Medical management of allergic symptoms after a sting depends on their severity.…”

Section: Who Requires Venom Immunotherapy?mentioning

confidence: 99%

Insect sting allergy in adults: key messages for clinicians

Nittner-Marszalska¹,

Cichocka‐Jarosz²

2015

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

In most affected persons, a Hymenoptera sting results in local itching and mild induration. There are some individuals, however, who additionally respond to a sting by developing sensitization manifested by the presence of venom-specific immunoglobulin E (IgE) antibodies (vsIgE) to various components of insect venoms (in honeybee venom, 12 allergens have been identified so far: Api m1 -Api m 12; in wasp venom, 5 allergens have been identified: Vesp v 1, V v 2, Vesp v 3, Vesp v5, and Ves v 6). 2 Venom sensitization is the key factor for but is not synonymous with venom allergy. Sensitization to Hymenoptera venoms may be asymptomatic (hypersensitivity not clinically relevant) or symptomatic defined as Hymenoptera--venom allergy (HVA). The asymptomatic sensitization is common and found in 9.3% to 40.7% of the general population and in 30% to 60% of beekeepers (which reflects the effect of exposition toThe occurrence of Hymenoptera-venom allergy Allergic reactions to insect bites result most frequently from stings of flying insects of the Hymenoptera order. From among over 100 000 species of Hymenoptera, the ones mainly responsible for sting reactions are usually honeybee (Apis mellifera) as well as wasps and hornets (eg, Vespula germanica, V. vulgaris, V. rufa, Vespae sp.). However, potential perpetrators of Hymenoptera allegry are diverse and vary with geography. In southern Europe, there are paper wasps (Polistinae subfamilies); in the United States, there are fire ants (Solenopsis invicta); and in Australia, there are Jack jumper ants (Myrmecia pilosula) that seem to cause more problems. A large number of Hymenoptera species, their ways of feeding, and their aggressive defense behavior result in as many as 56.6% to 94.5% of people experiencing at least 1 sting in their lives. ABSTRACTDuring their lifetime, 94.5% of people are stung by wasps, honeybees, hornets, or bumble-bees (order Hymenoptera). After a sting, most people show typical local symptoms, 5% to 15% develop local allergic reactions, and 3% to 8.9%-systemic allergic reactions (SARs), which may be potentially life-threatening in about 10% of them. In mild forms of Hymenoptera-venom allergy (HVA), the leading symptoms are urticaria and edema (grades I and II, respectively, according to the Mueller classification). Severe SARs are classified as grade III (respiratory symptoms) and IV (cardiovascular symptoms). Rare manifestations of HVA are Kounis syndrome and takotsubo cardiomyopathy. All patients after an SAR require standard (skin test, IgE, tryptase) or comprehensive (component diagnosis, basophil activation test) allergy testing. All patients with severe systemic symptoms (hypertension, disturbances in consciousness) should be tested for mastocytosis. Additionally, a relationship was found between the severity of HVA symptoms and intake of angiotensin-converting enzyme inhibitors (ACEIs). There is a similar concern, although less well-documented, about the use of β-blockers. Patients with HVA who have experienced a SAR are potential candidates for ...

show abstract

Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom

Cited by 151 publications

References 14 publications

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

Insect sting allergy in adults: key messages for clinicians

Contact Info

Product

Resources

About